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Objective: Due to cardiovascular safety concerns, the European Medicines Agency
(EMA) recommended new contraindications and changes to product information for
diclofenac across Europe in 2013. This study aims to measure their impact among
targeted populations.
Method: Quarterly interrupted time series regression (ITS) analyses of diclofenac ini-
tiation among cohorts with contraindications (congestive cardiac failure [CHF],
ischaemic heart disease [IHD], peripheral arterial disease [PAD], cerebrovascular dis-
ease [CVD]) and cautions (hypertension, hyperlipidaemia, diabetes) from Denmark,
the Netherlands, England and Scotland.
Results: The regulatory action was associated with significant immediate absolute
reductions in diclofenac initiation in all countries for IHD (Denmark −0.08%, 95%CI
−0.13, −0.03; England −0.09%, 95%CI −0.13 to −0.06%; the Netherlands −1.84%,
95%CI −2.51 to −1.17%; Scotland −0.34%, 95%CI −0.38 to −0.30%), PAD and
hyperlipidaemia, the Netherlands, England and Scotland for hypertension and diabe-
tes, and England and Scotland for CHF and CVD. Post-intervention there was a sig-
nificant negative trend in diclofenac initiation in the Netherlands for IHD (−0.12%,
95%CI −0.19 to −0.04), PAD (−0.13%, 95%CI −0.22 to −0.05), hypertension, hyper-
lipidaemia and diabetes, and in Scotland for CHF (−0.01%, 95%CI −0.02 to
−0.007%), IHD (−0.017, 95%CI −0.02, −0.01%), PAD and hypertension. In England,
diclofenac initiation rates fell less steeply. In Denmark changes were more strongly
associated with the earlier EMA 2012 regulatory action.
Conclusion: Although significant reductions in diclofenac initiation occurred, patients
with contraindications continued to be prescribed diclofenac, the extent of which
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varied by country and target condition. Understanding reasons for such variation
may help to guide the design or dissemination of future safety warnings.
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1 | INTRODUCTION
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) widely
prescribed for the management of inflammatory musculoskeletal con-
ditions.1 The cardiovascular risk of NSAIDs has resulted in significant
regulatory attention after safety concerns emerged over the use of
rofecoxib, which lead to its withdrawal.2 Further evidence concerning
the cardiovascular safety of NSAIDs later emerged, including a meta-
analysis of 280 randomised controlled trials demonstrating a signifi-
cantly increased risk of vascular events with use of celecoxib and
diclofenac.3
In 2013, these cardiovascular safety concerns prompted the
European Medicines Agency (EMA) Pharmacovigilance Risk Assess-
ment Committee (PRAC) to evaluate the safety of diclofenac.4–6 This
followed a review by the EMA's Committee for Medicinal Products
for Human Use (CHMP) in 2012.7 In 2013 the EMA PRAC concluded
that although diclofenac is an effective treatment for approved indica-
tions, an elevated risk of cardiovascular events occurs with systemic
exposure. For the benefit-risk of diclofenac to remain favourable, new
contraindications and warnings for prescribing diclofenac were rec-
ommended, along with changes to the product information and com-
munication of these measures using a Direct Healthcare Professional
Communication (DHPC) across Europe to alert prescribers to this
safety information. This communication highlighted that diclofenac
should be contraindicated in patients with congestive heart failure
(CHF), ischemic heart disease (IHD), peripheral arterial disease (PAD)
and/or cerebrovascular disease (CVD), and cautioned its use in
patients with certain cardiovascular risk factors (hypertension, hyper-
lipidaemia and diabetes mellitus).8 These are common cardiovascular
conditions among the general population and therefore the target
population is large.
Medicines regulatory actions are complex interventions and their
impact can vary, particularly by geographical location.9,10 Reasons for
variation in their impact are multiple and may relate to the intended
clinical indication, type of prescriber, method of dissemination, acces-
sibility of therapeutic alternatives, perceived importance by stake-
holders, type of target population and availability of downstream
opportunities to change clinical guidelines.11,12 Although the role of
regulatory agencies is to alert prescribers to new safety information,
the impact of such decisions on healthcare behaviour and health out-
comes is challenging to measure and often poorly understood, with
previous studies using heterogeneous and poor quality methods of
evaluation.12–14 We recently examined the impact of the 2013 EMA
intervention on overall diclofenac prescribing, discontinuation and
switching to alternative medicines in the general population.15 We
now report the impact of the 2013 EMA risk minimisation measures
for diclofenac among patients specifically targeted by the interven-
tion, namely among those with or at high risk of cardiovascular dis-
ease, across several EU countries to determine to what extent impact
may have varied.
2 | METHODS
2.1 | Data sources
Validated population data sources from four European countries were
analysed (see Supplementary Methods for details). In brief these
were:
• The Danish Register of Medicinal Products, which records all out-
of-hospital prescriptions and allows linkage of drug exposures to
inpatient and outpatient hospital contacts and death data.16–18
• The Dutch PHARMO Database Network, which contains combined
data from primary and secondary healthcare settings in the Neth-
erlands and the outpatient pharmacy database.19
What is already known about this subject
• Diclofenac is a widely prescribed analgesic in musculo-
skeletal disease.
• The European Medicines Agency (EMA) recommended
new contraindications and warnings for prescribing
diclofenac in people with cardiovascular disease that
were implemented across Europe in 2013.
What this study adds
• The EMA regulatory action was associated with signifi-
cant reductions in diclofenac initiation among the target
population.
• Some patients with contraindications continued to be
prescribed diclofenac, the extent of which varied
between country and target population.
• Further research is required to understand the reasons
for the variation in impact.
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• The United Kingdom Clinical Practice Research Datalink (CPRD),
which contains primary care data. For this analysis we used only
“up-to-standard” data from non-Scottish practices with the major-
ity being from England (90%).20
• The Scottish Prescribing Information System (PIS), which records
all medicines dispensed from pharmacies in Scotland that can be
record-linked to demographic data, Scottish Morbidity Records
and death registrations for the entire population.21
2.2 | Study population
Target population cohorts with a history of each contraindication or
caution were generated to provide aggregate time series data for anal-
ysis using a common protocol and format (EU PAS Register number
EUPAS24089).22 The availability of data from each database meant
that the study start period varied by data source. For each country
data were available from 2009Q1 to 2018Q1 in Denmark, 2008Q2 to
2016Q4 in the Netherlands, 2007Q1 to 2018Q1 in England and
2010Q3 to 2017Q4 in Scotland.
All patients from the target population cohorts were required to
have at least one year of observation (lookback period) prior to inclu-
sion in the cohort to allow sufficient time to determine prevalent ver-
sus incident use of diclofenac and the clinical conditions of interest.
Cohort entry was defined by the latest of the date of registration with
the general practice (in CPRD and PHARMO data sources) or the date
of first recorded prescription or any secondary care diagnosis
(in Danish and Scottish data sources) plus 1 year and the date of first
diagnosis of the condition of interest. Cohort exit was defined as the
first occurrence of any of the following: end of study period, end of
registration with the general practice (for data from England and the
Netherlands) or death (all databases). A patient was included in a time
period if patients were observable for the entire quarter, ie, the first
and last days of the quarter both lay between the patient's index date
and their last follow-up date. Patients were allowed to appear in more
than one target cohort providing they met each target cohort
definition.
2.3 | Exposures
The target population cohorts consisted of patients with a diagnosis
of the following contraindicated and cautioned groups (see Supple-
mentary Methods for full definitions) therefore seven open cohorts
were generated for each country. The contraindicated groups con-
sisted of CHF, IHD, PAD and CVD. The cautioned groups consisted of
hypertension, hyperlipidaemia and diabetes mellitus. Read, ICD or
ICPC codes were used to classify licenced indications into osteoarthri-
tis, acute gout (and other crystal arthropathies) and other inflamma-
tory arthropathies. The classification was based on any record dated
before the end of the time point.
2.4 | Outcome
The outcomes of interest were (a) the immediate change in diclofenac
initiation in the quarter following the date of the regulatory action
(prespecified as June 2013, ie, 2013Q2, when the EMA referral proce-
dure concluded) and (b) the change in diclofenac initiation trend post-
intervention compared to the baseline trend. Diclofenac initiation was
defined as a prescription for diclofenac with no exposure to diclofenac
in the preceding 92 days. The denominator was the number of
nonusers on the first day of the time period, defined as no exposure
to diclofenac in the previous 92 days. The numerator was the number
of these patients initiating diclofenac in the time period. Prevalent
users were therefore not included.
2.5 | Statistical analysis
Data were analysed as a series of proportions from aggregated
patient counts evaluated in each quarter over the study period.
Interrupted time series (ITS) regression analysis was used to fit quar-
terly time trends for each country (see Supplementary Methods for
further details). The effect of the intervention within each target
population in each country was represented either by a step func-
tion or by a continuous linear function modelling the baseline slope
before the intervention time point, the change in slope from the
baseline trend to the post-intervention trend and the immediate
change associated with the intervention time point.23 Before fitting
all regression models, data were visualised graphically. All regression
models were fitted separately in each country. The range of data
points was trimmed to periods immediately before and after June
2013 where trends were approximated to be linear when disconti-
nuities occurred. In a post hoc secondary analysis, we fitted the ITS
analysis for Denmark using the step change that occurred in quarter
three of 2012 coinciding with the diclofenac recommendation from
the CHMP.7 All models were checked for autocorrelation using
the Durbin-Watson statistic and analysis was carried out using
SAS V9.4.
2.6 | Ethical permissions
Permission to conduct the study in each database was obtained from
the relevant source from each country, according to each database's
standard terms and conditions (see Supplementary Methods for
further details).
2.7 | Public and patient involvement
This study was endorsed by the EMAs PRAC committee, which con-
sists of patient and healthcare professional representatives.
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3 | RESULTS
Among all target populations the most common indication for
diclofenac initiation was osteoarthritis. The proportion of patients ini-
tiating diclofenac at baseline with cardiovascular disease contraindica-
tions ranged from 0.6% (95%CI 0.6-0.7%) to 0.8% (95%CI 0.8-0.9%) in
Denmark, 6.6% (95%CI 3.8-11.1%) to 11.7% (95%CI 6.3-20.8%) in the
Netherlands, 0.2% (95%CI 0.2-0.3%) to 0.6% (95%CI 0.5-0.6%) in
England and 0.1% (95%CI 0.1-0.2%) in Scotland (Table 1).
Corresponding numbers for people with cautions were 1.0% (95%CI
0.9-1.0%) to 1.2% (95%CI 1.1 to 1.2%) in Denmark, 7.9% (95%CI
7.6-8.2%) to 8.4% (95%CI 7.7-8.7%) in the Netherlands, 0.6% (95%CI
0.6-0.6%) to 0.7% (95%CI 0.6-0.7%) in England and 0.1% to 0.3% in
Scotland (Table 1).
3.1 | Impact on diclofenac initiation in people
with CHF
The baseline trend of diclofenac initiation in patients with CHF was
positive in Scotland, negative in the Netherlands and there was no
trend in Denmark and England (Table 2 and Figures 1 and 2). The
regulatory action was associated with a significant immediate fall in
diclofenac initiation in patients with CHF in England (−0.08%, 95%CI
−0.12 to −0.05) and Scotland (−0.21%, 95%CI −0.24% to −0.18%).
Post-intervention, there was no significant change in trend compared
to baseline except for in Scotland, where there was a change from a
positive to a negative trend in diclofenac initiation (−0.011%, 95%CI
−0.015% to −0.007%).
3.2 | Impact on diclofenac initiation in people
with IHD
The baseline trend of diclofenac initiation in patients with IHD was
positive in Scotland, negative in England and the Netherlands, and
there was no trend in Denmark (Table 2 and Figures 1 and 2). The reg-
ulatory action was associated with a significant immediate fall in
diclofenac initiation in patients with IHD in all countries. Post-inter-
vention, there was a significant change to a negative trend in
diclofenac initiation in patients with IHD in the Netherlands
(−0.116%, 95%CI −0.193 to −0.038) and Scotland (−0.017%, 95%CI
−0.022 to −0.011) compared to baseline. In England, there was a pos-
itive change in trend, causing diclofenac initiation to fall significantly
less steeply, whilst in Denmark there was no significant change in
trend compared to baseline.
TABLE 1 Number of patients with each condition at the beginning of each cohort used for interrupted time series regression modelling
Denmark The Netherlands Englanda Scotland
Year/quarter start 2012Q2 2008Q3 2011Q3 2010Q2
Number of patients
Contraindicated group
CCF 70,081 77 31,760 45,432
IHD 234,273 1,833 149,185 181,618
PAD 59,323 354 79,531 39,188
CVD 131,414 183 86,634 61,271
Cautioned group
Hypertension 911,803 24,189 956,716 553,910
Hyperlipidaemia 622,836 13,427 612,004 531,739
Diabetes 231,610 5,467 201,204 161,399
Number of diclofenac initiators (%)
Contraindicated group
CCF 435 (0.6) 9 (11.7) 79 (0.2) 32 (0.1)
IHD 1,958 (0.8) 168 (9.2) 619 (0.4) 243 (0.1)
PAD 453 (0.8) 30 (8.4) 451 (0.6) 53 (0.1)
CVD 917 (0.7) 12 (6.6) 302 (0.3) 45 (0.1)
Cautioned group
Hypertension 10,623 (1.2) 1,907 (7.9) 6,398 (0.7) 1,650 (0.3)
Hyperlipidaemia 5,977 (1.0) 1,098 (8.2) 4,150 (0.7) 1,229 (0.2)
Diabetes 2,259 (1.0) 448 (8.2) 1,187 (0.6) 421 (0.3)
a10% of patients were from Northern Ireland and Wales.
Abbreviations: Q, quarter; CCF, congestive cardiac failure; IHD, ischaemic heart disease; PAD, peripheral arterial disease; CVD, cerebrovascular disease.
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3.3 | Impact on diclofenac initiation in people
with PAD
The baseline trend of diclofenac initiation in patients with PAD was
positive in Scotland, negative in England and there was no trend in
the Netherlands and Denmark (Table 2 and Figures 1 and 2). The
regulatory action was associated with a significant immediate fall in
diclofenac initiation in patients with PAD in all countries. Post-inter-
vention, there was a significant change to a negative trend in
diclofenac initiation in patients with PAD in the Netherlands
(−0.130%, 95%CI −0.216 to −0.045) and Scotland (−0.016%, 95%CI
−0.022 to −0.010) compared to baseline. In England, there was a
positive change in trend, causing diclofenac initiation to fall
significantly less steeply, and in Denmark there was no significant
change in trend.
3.4 | Impact on diclofenac initiation in people
with CVD
The baseline trend of diclofenac initiation in patients with CVD was
positive in Scotland, negative in England and the Netherlands, and
there was no trend in Denmark (Table 2 and Figures 1 and 2). The reg-
ulatory action was associated with a significant immediate fall in
diclofenac initiation in patients with CVD in the Netherlands (−1.88%,
95%CI −2.78 to −0.98), England (−0.073%, 95%CI −0.103 to −0.043)
TABLE 2 Interrupted time series regression analysis for diclofenac initiation by contraindicated group targeted by the regulatory intervention
per country
Slope before June 2013
Step change in the first quarter after June
2013 Slope change after June 2013
Congestive heart failure
Denmark −0.007 (−0.031, 0.016), P = 0.521 −0.051 (−0.121, 0.018), P = 0.137 −0.001 (−0.024, 0.023), P = 0.954
Englanda −0.004 (−0.010, 0.003), P = 0.248 −0.084 (−0.118, −0.051), P <0.001 0.002 (−0.005, 0.009), P = 0.524
Netherlands −0.201 (−0.321, −0.081),
P = 0.002
−1.272 (−2.599, 0.056), P = 0.060 0.005 (−0.153, 0.163), P = 0.949
Scotland 0.008 (0.004, 0.011), P <0.001 −0.211 (−0.243, −0.179), P <0.001 −0.011 (−0.015, −0.007),
P <0.001
Ischaemic heart disease
Denmark 0.005 (−0.013, 0.023), P = 0.568 −0.078 (−0.131, −0.025), P = 0.007 −0.014 (−0.032, 0.004), P = 0.118
Englanda −0.015 (−0.022, −0.008),
P <0.001
−0.094 (−0.132, −0.056), P <0.001 0.011 (0.004, 0.019), P = 0.006
Netherlands −0.077 (−0.128, −0.026),
P = 0.005
−1.838 (−2.508, −1.168), P <0.001 −0.116 (−0.193, −0.038),
P = 0.005
Scotland 0.012 (0.007, 0.016), P <0.001 −0.339 (−0.381, −0.297), P <0.001 −0.017 (−0.022, −0.011),
P <0.001
Peripheral arterial
disease
Denmark 0.012 (−0.018, 0.043), P = 0.396 −0.097 (−0.186, −0.008), P = 0.034 −0.024 (−0.055, 0.006), P = 0.111
Englanda −0.023 (−0.032, −0.015),
P <0.001
−0.093 (−0.135, −0.050), P <0.001 0.017 (0.008, 0.025), P <0.001
Netherlands −0.057 (−0.124, 0.010), P = 0.093 −2.023 (−2.676, −1.371), P <.001 −0.130 (−0.216, −0.045),
P = 0.004
Scotland 0.011 (0.005, 0.016), P <0.001 −0.257 (−0.306, −0.208), P <0.001 −0.016 (−0.022, −0.010),
P <0.001
Cerebrovascular disease
Denmark 0.013 (−0.022, 0.047), P = 0.440 −0.073 (−0.174, 0.028), P = 0.143 −0.025 (−0.060, 0.010), P = 0.143
Englanda −0.013 (−0.019, −0.007),
P <0.001
−0.073 (−0.103, −0.043), P <0.001 0.009 (0.003, 0.015), P = 0.006
Netherlands −0.089 (−0.167, −0.010),
P = 0.028
−1.878 (−2.781, −0.975), P <0.001 −0.074 (−0.181, 0.033), P = 0.168
Scotland 0.012 (0.008, 0.015), P <0.001 −0.235 (−0.264, −0.206), P <0.001 −0.015 (−0.019, −0.011),
P <0.001
a10% of patients were from Northern Ireland and Wales.
Trends in diclofenac initiation rates are percentages per quarter.
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and Scotland (−0.235%, 95%CI −0.264 to −0.206), but not in Den-
mark. Post-intervention, there was a significant change to a negative
trend in diclofenac initiation in patients with CVD in Scotland
(−0.015%, 95%CI −0.019 to −0.011) compared to baseline. In
England, there was a positive change in trend, causing diclofenac initi-
ation to fall significantly less steeply, and in the Netherlands and Den-
mark there was no significant change in trend.
3.5 | Impact on diclofenac initiation in people with
hypertension
The baseline trend of diclofenac initiation in patients with hyperten-
sion was negative in England and there was no trend in Denmark,
Scotland and the Netherlands (Table 3 and Figures 3 and 4). The regu-
latory action was associated with a significant immediate fall in
diclofenac initiation in patients with hypertension in all countries apart
from in Denmark. Post-intervention, there was a significant change to
a negative trend in diclofenac initiation in patients with hypertension
in the Netherlands (−0.121%, 95%CI −0.202 to −0.040) and Scotland
(−0.028%, 95%CI −0.046 to −0.010) compared to baseline. In
England, there was a positive change in trend, causing diclofenac initi-
ation to fall significantly less steeply, and in Denmark there was no
significant change in trend.
3.6 | Impact on diclofenac initiation in people with
hyperlipidaemia
The baseline trend of diclofenac initiation in patients with hyper-
lipidaemia was falling in England and Scotland and there was no trend
in Denmark and the Netherlands (Table 3 and Figures 3 and 4). The
regulatory action was associated with a significant immediate fall in
diclofenac initiation in patients with hyperlipidaemia in all countries.
Post-intervention, there was a significant change to a negative trend
in diclofenac initiation in the Netherlands (−0.143%, 95%CI −0.222 to
−0.063) compared to baseline. Post-intervention, there was a positive
change in trend in diclofenac initiation in England, causing it fall signif-
icantly less steeply, while in Denmark and Scotland there was no sig-
nificant change in trend.
3.7 | Impact on diclofenac initiation in people with
diabetes
The baseline trend of diclofenac initiation in patients with diabetes
was negative in England and Scotland compared to in Denmark and
the Netherlands, where it was flat (Table 3 and Figures 3 and 4). The
regulatory action was associated with a significant immediate fall in
diclofenac initiation in patients with diabetes in all countries except
F IGURE 1 Diclofenac initiation rates in patients with new contraindications following the 2013 EMA regulatory action in (A) Denmark and
(B) the Netherlands
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Denmark. Post-intervention, there was a significant change to a nega-
tive trend in diclofenac initiation in the Netherlands (−0.131%, 95%CI
−0.221 to −0.041) compared to baseline, while in England there was
a positive change in the trend, causing diclofenac initiation to fall less
steeply, while in Denmark and Scotland there was no significant
change in trend.
3.8 | Secondary analysis
The step change occurring in 2012Q3 in Denmark coinciding with the
CHMP review was associated with a significant immediate fall in
diclofenac initiation among all contraindicated and cautioned groups,
and significant slowing in the negative baseline trend in diclofenac ini-
tiation (Supporting InformationTable S1 and Figure S1).
4 | DISCUSSION
The 2013 EMA regulatory action focusing on the cardiovascular
safety of systemic diclofenac products had a significant impact on
diclofenac initiation among patients with target cardiovascular disease
contraindications and cautions, the magnitude and type of which var-
ied between countries. In patients with IHD, PAD and hyper-
lipidaemia, diclofenac initiation immediately fell in all countries.
However, the impact on longer-term prescribing in patients with or at
high risk of cardiovascular disease was more variable. The Netherlands
had the highest prevalence of diclofenac prescribing. In Scotland, sig-
nificant reductions in diclofenac initiation occurred in all target
populations apart from in patients with hyperlipidaemia and diabetes,
whilst in England longer-term changes were associated with a slowing
in an already falling rate. In Denmark, small immediate falls in
diclofenac initiation were observed in patients with IHD, PAD and
hyperlipidaemia only, without any significant changes in longer-term
prescribing, suggesting that the 2013 EMA referral procedure may
have had a limited impact in Denmark.
We observed similar changes in target populations as among the
population as a whole, but percentile changes tended to be larger. For
example, the regulatory action was associated with a −0.42% signifi-
cant immediate step reduction in diclofenac initiation in the Nether-
lands among the overall population compared to −1.3%, −1.8%,
−2.0% and −1.9% among those with CHF, IHD, PAD and CVD,
respectively.15 A similar effect was seen with significant changes in
post-intervention trend and suggests that the effect of the regulatory
action was more concentrated among the target populations.
Limited impact of the EMA regulatory action has been noted in
Lithuania, where diclofenac prescribing remained unchanged.24 Geo-
graphical variation in impact is not new and has been associated with
other types of regulatory procedures.10 Variation in impact may relate
to cultural differences in prescribing and pharmacovigilance practices
between countries, for example whether diclofenac is prescribed
short term or long term, and the clinical indication.25,26 In our
F IGURE 2 Diclofenac initiation rates in patients with new contraindications following the 2013 EMA regulatory action in (A) England and
(B) Scotland
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population, osteoarthritis was the most common indication,
suggesting it was potentially used longer term, conferring a larger risk.
In absolute terms, diclofenac initiation was greater in the Netherlands
compared to Denmark, where other NSAIDs have been preferentially
prescribed.27 Given that numerous NSAID products exist, it is unlikely
that lack of availability of therapeutic alternatives would explain such
differences.
Safety communications need to reach their target audience to be
effective, therefore differences in the effectiveness of communication
and dissemination strategies may impact on healthcare professional
awareness.12,28 When a decision is taken to communicate information
using a DHPC as part of the EMA referral, there is an obligation for
the DHPC to be disseminated among all member states although the
actual timing of this may not be the same. The effectiveness of this
dissemination is often unknown but differences in how many
healthcare professionals receive the DHPC is one potential explana-
tion for some of this variation. Diclofenac is also commonly prescribed
by general practitioners, who might be more aware of such safety
issues than specialists.11,29 For example, evidence suggests that cardi-
ologists are much more likely to be aware of safety issues regarding
medicines they prescribe compared to the cardiovascular safety issues
related to medicines that other healthcare professionals prescribe.11
Our analysis is currently the largest study examining the impact
of the 2013 EMA regulatory action on diclofenac initiation among
patients with cardiovascular disease contraindications and cautions in
Europe.1,30,31 Historically, studies evaluating the impact of regulatory
actions have been subject to methodological limitations, which has led
to calls for robust methods to ensure that results are valid and infor-
mative.32 The use of large, high-quality data sources and a common
protocol and data format to standardise analysis from each data
source are therefore particular strengths of this study.11,12
This study has several limitations. First, although over-the-
counter (OTC) NSAID use was not captured, the primary objective
was to assess the impact of regulatory action on healthcare profes-
sional prescribing, which is only indirectly reflected in OTC use.
Diclofenac was not widely available OTC in these countries. For
example, although diclofenac OTC status was revoked in the UK in
2015 in response to these ongoing safety concerns, ibuprofen was
the much more commonly available OTC NSAID used.33 Diclofenac
is only available OTC in the Netherlands as a low-strength product
and no specific changes in this status have occurred over this time,
whilst diclofenac has not been available OTC in Denmark.34 Second,
ITS analysis requires that the date of the regulatory action be
prespecified and trends may be affected by other confounding fac-
tors occurring simultaneously or at other points in time.24 Due to
such obvious changes in baseline trend that can violate linear
regression model assumptions, only a small number of baseline time
periods prior to the outcome of regulatory action from Denmark
were included in the analysis. This may have reduced the power to
detect significant changes associated with the conclusion of the
2013 EMA PRAC review.24,35 Similarly, detecting significant changes
associated with regulatory actions may be more difficult if baseline
trends are already heading in the intended direction. In Denmark
TABLE 3 Interrupted time series regression analysis for
diclofenac initiation by cautioned group targeted by the regulatory
intervention per country
Slope before
June 2013
Step change in
first quarter
after June 2013
Slope change
after June
2013
Hypertension
Denmark 0.013
(−0.029,
0.056),
P = 0.509
−0.116 (−0.239,
0.008),
P = 0.065
−0.033
(−0.075,
0.010),
P = 0.123
Englanda −0.023
(−0.028,
−0.018),
P = <0.001
−0.134 (−0.160,
−0.107),
P = <0.001
0.016 (0.010,
0.021),
P = <0.001
Netherlands −0.016
(−0.065,
0.033),
P = 0.513
−1.491 (−2.198,
−0.785),
P = <0.001
−0.121
(−0.202,
−0.040),
P = 0.005
Scotland −0.004
(−0.020,
0.013),
P = 0.648
−1.051 (−1.194,
−0.908),
P = <0.001
−0.028
(−0.046,
−0.010),
P = 0.004
Hyperlipidaemia
Denmark 0.016
(−0.021,
0.052),
P = 0.369
−0.108 (−0.214,
−0.001),
P = 0.048
−0.031
(−0.068,
0.006),
P = 0.091
Englanda −0.026
(−0.032,
−0.020),
P = <0.001
−0.125 (−0.155,
−0.094),
P = <0.001
0.018 (0.012,
0.025),
P = <0.001
Netherlands −0.016
(−0.066,
0.033),
P = 0.506
−1.550 (−2.242,
−0.859),
P = <0.001
−0.143
(−0.222,
−0.063),
P = <0.001
Scotland −0.022
(−0.032,
−0.011),
P = <0.001
−0.704 (−0.798,
−0.610),
P = <0.001
0.002
(−0.010,
0.013),
P = 0.791
Diabetes
Denmark 0.011
(−0.033,
0.055),
P = 0.597
−0.077 (−0.206,
0.052),
P = 0.223
−0.026
(−0.071,
0.018),
P = 0.228
Englanda −0.024
(−0.031,
−0.017),
P = <0.001
−0.101 (−0.136,
−0.066),
P = <0.001
0.017 (0.010,
0.025),
P = <0.001
Netherlands −0.028
(−0.083,
0.027),
P = 0.312
−1.488 (−2.275,
−0.701),
P = <0.001
−0.131
(−0.221,
−0.041),
P = 0.006
Scotland −0.020
(−0.030,
−0.010),
P = <0.001
−0.668 (−0.754,
−0.582),
P = <0.001
0.000
(−0.011,
0.011),
P = 0.997
a10% of patients were from Northern Ireland and Wales.
Trends in diclofenac initiation rates are percentages per quarter.
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significant changes in prescribing may have occurred pre-interven-
tion. The EMA CHMP reported potential safety concerns with
NSAIDs in September 2012 that led to the PRAC safety review.7 In
post hoc analysis, when the intervention date was moved in line
with the CHMP procedure in Denmark, significant immediate falls in
diclofenac initiation were observed among all target populations. It
is therefore possible that changes in diclofenac initiation in Denmark
were influenced by regulatory action, but these changes may not
have been attributable to the 2013 PRAC recommendations. It is
possible that other factors may have influenced baseline trends in
England, although these may have occurred before the outcome of
the 2012 CHMP review.
The purpose of examining the impact of regulatory actions affect-
ing people with or at high risk of cardiovascular disease is to deter-
mine whether regulatory action has been successful or not. This
judgement is complex, however, and it is not always possible for
prespecified thresholds of success to be defined. Our data suggest
that although significant changes in prescribing occurred, there is per-
haps room for improvement due to the fact that in all countries
diclofenac initiation still occurred in some patients with known
cardiovascular disease contraindications. Given the differences in pre-
scribing rates and variation in impact, the decision as to whether fur-
ther regulatory action is warranted to reinforce cardiovascular safety
warnings may be better taken at national level among those countries
studied. No firm recommendation can be made for member states
that were not studied, where an EU-wide assessment would require
better infrastructure and funding to support access and analysis of
data from all EU member states.
In conclusion, the outcome of the 2013 EMA PRAC regulatory
action on the cardiovascular safety of diclofenac had a significant
impact on reducing diclofenac initiation among patients with cardio-
vascular disease contraindications and cautions, although some
patients with contraindications still continue to be prescribed
diclofenac in all countries. In Denmark these changes appear more
strongly associated with the 2012 EMA CHMP review rather the
2013 EMA PRAC recommendations.
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